Last reviewed · How we verify

NCT06705101

Gabapentin and Pressor Response to Intubation

Not yet recruiting Phase 1, PHASE2 Last updated 26 November 2024
What this trial tests

Phase 1, PHASE2 trial testing Gabapentin Group (Group G): Patients will receive 300 mg of oral Gabapentin in Elective Surgical Patients in 144 participants. Not yet recruiting.

Timeline
15 December 2024
Primary endpoint
15 June 2025
16 July 2025

Quick facts

Lead sponsorLiaquat National Hospital & Medical College
PhasePhase 1, PHASE2
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeprevention
Enrollment144
Start date15 December 2024
Primary completion15 June 2025
Estimated completion16 July 2025

Drugs / interventions tested

Conditions studied

Sponsor

Liaquat National Hospital & Medical College

Who can join

Adults 18 to 59, any sex, with Elective Surgical Patients or Blood Pressure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the effectiveness of oral gabapentin in reducing the pressor response (increased MAP, HR, and BP) during laryngoscopic intubation. It is a prospective, double-blind randomized controlled trial involving 144 patients undergoing elective surgery. Gabapentin 300 mg or placebo will be administered preoperatively, with hemodynamic parameters monitored before and after intubation. The study aims to determine if gabapentin attenuates the sympathetic stress response compared to placebo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Liaquat National Hospital & Medical College trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06705101.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing